{"entity":{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","aka":[],"tldr":"A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.","summary":"MammaPrint is Agendia's 70-gene signature. MINDACT (n=6,693): women with high clinical but low genomic risk had 5-year distant metastasis-free survival of 94.7% without chemotherapy; 8-year update showed a small benefit of chemotherapy in women under 50. FDA-cleared (2007), NCCN-listed alongside Oncotype DX; BluePrint adds molecular subtyping. Also used to identify 'ultralow' risk tumours with indolent behaviour.","status":"established","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/MammaPrint","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/MammaPrint"}],"tags":[],"related":[],"cancers":["breast-hr-positive","hr-positive-early-high-risk"],"sections":[],"technologies":["rna-seq","companion-diagnostic","gene-expression-prognostic-assays"],"targets":[],"drugs":[],"companies":["agendia"],"institutions":[],"pathways":[],"terms":[],"trials":["mindact","tailorx"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Gene-expression prognostic assay","mechanism":"Microarray or NGS expression of 70 genes → dichotomous low/high risk.","approvals":[{"region":"US","year":2007,"indication":"FDA 510(k) clearance for recurrence risk in early breast cancer"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mammaprint/","neighbours":{"cancer":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"agendia","kind":"company","name":"Agendia","route":"/companies/agendia/"}],"trial":[{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/"},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/"}],"pairing":[{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/"}],"drug":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"},{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/"}],"person":[{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/"}],"term":[{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/"}],"roadmap":[{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"}]}}